Abstracts tagged "Systemic sclerosis"

Abstract Number: 1047 • ACR Convergence 2021
Exposure to Industrial Pollutants and Mortality Due to Inmune-mediated Inflammatory Systemic Diseases (IMD) in Spain
ana Perez¹, Arturo Rodriguez Pérez², Pablo Fernandez-Navarro³, Fernando Albarran⁴, Cristina Bohorquez⁴, Atusa Movasat⁴, Lucia Ruiz⁴, Paula Pretel⁴, elena Rabadan⁴, Valentina Emperiale⁴, Adrian abbasi⁵, julio suarez⁵, Lorena Montano⁴, emilio rico⁵, alfredo prieto², melchor Alvarez de Mon⁵ and beatriz perez³, ¹Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, ²Faculty of Medicine. Alcala University, Alcala de Henares, Spain, ³Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain, ⁴Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, ⁵Hospital Universitario Príncipe de Asturias, Madrid, Spain
Background/Purpose: The etiology of many IMD is largely unknown; however, available data suggest that environmental contaminants could play a role in their origin. Industrial facilities…
Abstract Number: 1382 • ACR Convergence 2021
Survey on Treatment Practices in Subclinical Interstitial Lung Disease in Systemic Sclerosis
Sabrina Hoa¹, Murray Baron² and Marie Hudson³, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Jewish General Hospital, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc). Early detection and treatment of SSc-ILD may lead to improved…
Abstract Number: 1840 • ACR Convergence 2021
Can Dual-energy CT Lung Perfusion Detect Abnormalities at the Level of Lung Circulation in Systemic Sclerosis (SSc) ? Preliminary Experience in 101 Patients
Vincent Koether¹, Antoine Dupont², Julien Labreuche³, Paul Felloni⁴, Thierry Perez⁵, Pascal Degroote⁵, Jacques Remy⁴, Martine Remy-Jardin⁵ and David Launay⁶, ¹CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de référence des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ²CHRU de Lille, Hopital Calmette, Lille, France, ³CHU Lille, Lille, ⁴CHU Lille; Hopital Calmette, Lille, France, ⁵CHU Lille, Lille, France, ⁶Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille Cedex, France
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder that is characterized by a interplay of vascular abnormalities, immune system activation and an uncontrolled fibrotic response…
Abstract Number: 1861 • ACR Convergence 2021
Epidermal Growth Factor Receptor Pathway and Fibrosis in Systemic Sclerosis Skin
Miruna Carnaru¹, Monique Hinchcliff², Ian Odell¹ and F. Perry Wilson³, ¹Yale School Of Medicine, New Haven, CT, ²Yale School of Medicine, Westport, CT, ³Section of Nephrology, Department of Medicine, Yale School of Medicine, New Haven, CT; Department of Medicine Clinical and Translational Research Accelerator Yale School of Medicine, New Haven, CT
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disorder with chronic morbidity and high mortality. Disease pathogenesis involves microvascular damage, immune dysregulation, and fibrosis affecting…
Abstract Number: 0404 • ACR Convergence 2021
Perifollicular Hypopigmentation in Systemic Sclerosis: Associations with Clinical Features and Internal Organ Involvement
Melody Chung¹, Jamie Perin¹, Carrie Richardson², Christopher Mecoli³, Fred Wigley¹ and Zsuzsanna McMahan⁴, ¹Johns Hopkins University, Baltimore, MD, ²Rush University Medical Center, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Among the autoimmune rheumatic diseases, there is precedent for utilizing cutaneous manifestations of systemic disease as clues to clinical phenotype and disease prognosis. Though…
Abstract Number: 0551 • ACR Convergence 2021
Metabolic Intermediate Dimethyl-Alpha-Ketoglutarate Is a Novel Repressor of Pathogenic Myofibroblast Reprogramming and Skin Fibrosis in Systemic Sclerosis
Blaž Burja¹, Ishani Banik², Shervin Assassi³, Michael Whitfield⁴, J. Matthew Mahoney⁵, Andreja Erman⁶, Matija Tomšič⁷, Mitchell P. Levesque², Snežna Sodin-Šemrl⁷, Gabriela Kania⁸, Hubert Rehrauer⁹, Ziga Rotar⁷, Oliver Distler¹⁰, Katja Lakota¹¹ and Mojca Frank-Bertoncelj¹⁰, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich and Department of Rheumatology, University Medical Centre Ljubljana, Zurich, Switzerland, ²Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³University of Texas McGovern Medical School at Houston, Houston, TX, ⁴Geisel School of Medicine, Lebanon, NH, ⁵Center for Quantitative Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁶Institute for Cell Biology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁷Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁹Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich, Switzerland, ¹⁰Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ¹¹Department of Rheumatology, University Medical Centre Ljubljana, Llubljana, Slovenia
Background/Purpose: Metabolic perturbations drive fibroblast-to-myofibroblast reprogramming and tissue fibrosis. Restoring perturbed metabolism might represent a new antifibrotic strategy. Here we explored the capacity of dimethyl-alpha-ketoglutarate…
Abstract Number: 1048 • ACR Convergence 2021
Estimating the Weight of Rheumatologic Diseases in Mortality in Spain: Basic Cause of Death vs Multiple Cause Analysis
ana Perez¹, Fernando Albarran², Cristina Bohorquez², Atusa Movasat², Lucia Ruiz², Paula Pretel², elena Rabadan², Valentina Emperiale², Adrian abbasi³, julio suarez³, lorena montano³, emilio rico³, alfredo prieto⁴, Inmaculada Leon⁵, melchor Alvarez de Mon³ and beatriz perez⁶, ¹Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, ²Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, ³Hospital Universitario Príncipe de Asturias, Madrid, Spain, ⁴Faculty of Medicine. Alcala University, Alcala de Henares, Spain, ⁵Communicable Diseases. Instituto de Salud Carlos III, Madrid, Spain, ⁶Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain
Background/Purpose: Classical statistics provide information on mortality rates for basic causes of death. Although many inflammatory rheumatic diseases decrease life expectancy, they are generally not…
Abstract Number: 1384 • ACR Convergence 2021
A Genomic Meta-Analysis of Clinical Variables and Association with Intrinsic Molecular Subsets in Systemic Sclerosis
Jennifer Franks¹, Diana Toledo¹, Viktor Martyanov¹, Yue Wang², Suiyuan Huang³, Tammara Wood¹, Cathie Spino³, Robyn Domsic⁴, Monique Hinchcliff⁵, Dinesh Khanna³ and Michael Whitfield⁶, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Geisel School of Medicine at Dartmouth, West Lebanon, NH, ³University of Michigan, Ann Arbor, MI, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Yale School of Medicine, Westport, CT, ⁶Geisel School of Medicine, Lebanon, NH
Background/Purpose: Four intrinsic molecular subsets (Inflammatory, Fibroproliferative, Limited, Normal-like) have been identified in systemic sclerosis (SSc) that may have different clinical associations. To test this…
Abstract Number: 1841 • ACR Convergence 2021
Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases
Louisa-Marie Mockenhaupt¹, Ramona Dolscheid-Pommerich¹, Charlotte Behning¹, Birgit Stoffel-Wagner², Peter Brossart¹ and Valentin Schäfer¹, ¹University Hospital Bonn, Bonn, Germany, ²University Hospital Bonn, Bonn
Background/Purpose: Antinuclear antibodies (ANA) are serological markers for the presence of connective tissue diseases [1]. In some patients, a pattern can be detected in ANA…
Abstract Number: 0405 • ACR Convergence 2021
Retrospective Study on the Prognostic Value of Cardiac Magnetic Resonance Imaging Abnormalities in Systemic Sclerosis
Hao Cheng Shen¹, Catherine Faucher², Anne Chin³, Carl Chartrand-Lefebvre³, Ragui Chehata⁴, Julia Cadrin-Tourigny⁵, Francois-Pierre Mongeon⁶, Jean-Paul Makhzoum⁷, Océane Landon-Cardinal⁸, Josiane Bourré-Tessier⁸, Éric Rich⁹, Jean-Richard Goulet⁸, Paul R Fortin¹⁰, Jean-Luc Senécal⁸ and Sabrina Hoa⁸, ¹Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Department of Medicine, Université Laval, Québec, QC, Canada, ³Department of Radiology, Centre hospitalier de l’Université de Montréal, Montréal, QC, Canada, ⁴Department of Medicine, Université de Montréal, Montreal, Montréal, QC, Canada, ⁵Division of Non-Invasive Cardiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁶Division of electrophysiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁷Division of Internal Medicine, Hôpital Sacré-Coeur de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁸Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁹Division of Rheumatology, Centre hospitalier de l’Université de Québec-Université Laval, Montréal, QC, Canada, ¹⁰CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Cardiac involvement is a leading cause of death in systemic sclerosis (SSc). Cardiac MRI (CMR) is useful in the early assessment of cardiac disease.…
Abstract Number: 0554 • ACR Convergence 2021
Reverse Signaling Through PD-L1 Plays a Central Role in Extracellular Matrix Protein Secretion from Cutaneous Myofibroblasts in Systemic Sclerosis
Maithri Aspari¹, Stinne Greisen¹, Malene Hvid¹, Klaus Sondergaard², Voon Ong³, Christopher Denton⁴, David Abraham⁵ and Bent Deleuran¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University Hospital, Aarhus, Denmark, ³University College London Medical School Royal Free Campus, London, United Kingdom, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁵University College London, London, United Kingdom
Background/Purpose: The PD-1/PD-L1 pathway has been implicated in Systemic Sclerosis (dSSc). This disease is dominated by increased extracellular matrix deposition initiated by myofibroblasts. We therefore…
Abstract Number: 1099 • ACR Convergence 2021
Characteristics and Outcomes of Myocardial Infarction in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Gout and Osteoarthritis Patients Using the National Inpatient Sample Database from 2002-2018
Sonia Gupta¹, Vinay thallapally², Sarah Aurit², Rouhin sen³ and Joseph Nahas², ¹Creighton University School of Medicine, Omaha, NE, ²Creighton University, Omaha, NE, ³Colorado University Anschutz Medical Campus, Denver, CO
Background/Purpose: Patients with the autoimmune rheumatic disease have an increased risk of acute myocardial infarction (MI). Our study was designed to compare the prevalence, characteristics…
Abstract Number: 1385 • ACR Convergence 2021
Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study
Jason Melehani¹, Shufeng Li², Joshua Mooney³ and Lorinda Chung², ¹Stanford University, San Jose, CA, ²Stanford University, Palo Alto, CA, ³Stanford University, Stanford, CA
Background/Purpose: Lung manifestations of systemic autoimmune diseases are a frequent cause of early death. For many patients, current treatments cannot arrest the inexorable progression to…
Abstract Number: 1842 • ACR Convergence 2021
Peripheral Blood Cell Gene Expression Profiling Predicts Response to Mycophenolate in Systemic Sclerosis Related Interstitial Lung Disease
Shervin Assassi¹, Wenjin Zheng², Elizabeth Volkmann³, Xuan Wang⁴, Holly Wilhalme⁵, Marka Lyons⁶, Michael Roth⁵ and Donald Tashkin⁵, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²School of Biomedical Informatics at the University of Texas Health Science Center at Houston, Houston, TX, ³Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, ⁴Baylor Scott & White Health, Dallas, TX, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX
Background/Purpose: Response to immunosuppression is variable in systemic sclerosis (SSc) related interstitial lung disease (ILD). Contrary to pulmonary tissue, peripheral blood cell (PBC) RNA can…
Abstract Number: 0142 • ACR Convergence 2021
Description of a Scleroderma Cohort and Management of Lung Disease Risk at a Rural Academic Medical Center
Jenna Marinock¹, P. Daniel Nicholas², Kirsten Koons³, Rakesh Kriplani⁴, Andrea Berger⁴ and David Bulbin⁵, ¹Geisinger Commonwealth School of Medicine, Philadelphia, PA, ²Geisinger Medical Center, Danville, PA, ³Geisinger Medical Center, Lewisburg, PA, ⁴Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, ⁵Geisinger Health System, Danville, PA
Background/Purpose: Systemic sclerosis interstitial lung disease (SSc-ILD) and pulmonary hypertension (SSc-PH) are leading causes of morbidity and mortality in patients with SSc. Few screening guidelines…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].